United States - English - NLM (National Library of Medicine)

sola pharmaceuticals, llc - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see  warnings ).

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose leucine - prevention of the onset of lactation in the puerperium only for clearly defined medical reasons: arrow - cabergoline is indicated for the inhibition of physiological lactation soon after delivery. 1. after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. 2. after stillbirth or abortion. treatment of hyperprolactinaemic disorders: cabergoline is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cabergoline, quantity: 500 microgram - tablet - excipient ingredients: lactose; magnesium stearate - ? inhibition of physiological lactation ,cabergoline is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. ,? treatment of hyperprolactinaemic disorders ,cabergoline is indicated for the treatment of pathological hyperprolactinaemia.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cabergoline - oral tablet - 1mg

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - cabergoline - tablet - cabergoline

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - cabergoline - oral tablet - 1mg

Malta - English - Medicines Authority

teva pharma b.v. (mijdrecht) industrieweg 23, p.o. box 217, 3640 ae mijdrecht, netherlands - cabergoline - tablet - cabergoline 0.5 mg - other gynecologicals

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - tablet - cabergoline 0.5 mg - other gynecologicals